406 related articles for article (PubMed ID: 28210841)
1. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
[TBL] [Abstract][Full Text] [Related]
2. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
3. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
Front Immunol; 2021; 12():690821. PubMed ID: 34177949
[TBL] [Abstract][Full Text] [Related]
4. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab in the treatment of membranoproliferative glomerulonephritis.
Bomback AS
Nephron Clin Pract; 2014; 128(3-4):270-6. PubMed ID: 25402185
[TBL] [Abstract][Full Text] [Related]
6. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?
Ankawi GA; Clark WF
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28798244
[TBL] [Abstract][Full Text] [Related]
7. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
8. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome.
Tawadrous H; Maga T; Sharma J; Kupferman J; Smith RJ; Schoeneman M
Pediatr Nephrol; 2010 May; 25(5):947-51. PubMed ID: 20108004
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
Noris M; Galbusera M; Gastoldi S; Macor P; Banterla F; Bresin E; Tripodo C; Bettoni S; Donadelli R; Valoti E; Tedesco F; Amore A; Coppo R; Ruggenenti P; Gotti E; Remuzzi G
Blood; 2014 Sep; 124(11):1715-26. PubMed ID: 25037630
[TBL] [Abstract][Full Text] [Related]
11. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
12. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
13. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
Frémeaux-Bacchi V; Fakhouri F; Roumenina L; Dragon-Durey MA; Loirat C
Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430
[TBL] [Abstract][Full Text] [Related]
14. [Complement factor B mutation in atypical hemolytic uremic syndrome. Rare cause of rare disease].
Visconti L; Cernaro V; Ardissino G; Sgarbanti M; Ferrara D; Visconti G; Santoro D; Buemi M
G Ital Nefrol; 2017 Apr; 34(2):74-81. PubMed ID: 28682564
[TBL] [Abstract][Full Text] [Related]
15. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
16. Anti-complement therapy for glomerular diseases.
Bomback AS
Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.
Békássy ZD; Kristoffersson AC; Cronqvist M; Roumenina LT; Rybkine T; Vergoz L; Hue C; Fremeaux-Bacchi V; Karpman D
Nephrol Dial Transplant; 2013 Nov; 28(11):2899-907. PubMed ID: 24009284
[TBL] [Abstract][Full Text] [Related]
18. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
Belingheri M; Possenti I; Tel F; Paglialonga F; Testa S; Salardi S; Ardissino G
Pediatrics; 2014 Jun; 133(6):e1769-71. PubMed ID: 24843058
[TBL] [Abstract][Full Text] [Related]
19. A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome.
Funato M; Uemura O; Ushijima K; Ohnishi H; Orii K; Kato Z; Yamakawa S; Nagai T; Ohara O; Kaneko H; Kondo N
J Clin Immunol; 2014 Aug; 34(6):691-5. PubMed ID: 24906628
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
